Cancer Epidemiology and Prevention
The Cancer Epidemiology and Prevention program at Harvard T.H. Chan School of Public Health is one of the first comprehensive academic programs in the world dedicated to the training of cancer epidemiologists.
Epidemiology Department
677 Huntington Ave
Kresge, Floor 9
Boston, MA 02115
About the Program
The program’s curriculum includes a breadth of courses on cancer research methodology, substantive courses on cancer epidemiology and prevention, as well as courses on genetic epidemiology and biomarkers. The courses are aimed at enhancing the skills and training of cancer epidemiologists through the integration of biologic and environmental factors into a deeper understanding of disease etiology and for translation into cancer control.
The Cancer Epidemiology and Prevention program at Harvard T.H. Chan School of Public Health is one of the first comprehensive academic programs in the world dedicated to the training of cancer epidemiologists.
Students and fellows in the program work closely with faculty who are conducting cutting-edge research into the lifestyle, environmental, and genetic factors that influence both cancer incidence and survival with studies both in the U.S. and globally. Research covers a broad array of malignancies including breast, colorectal, lung, nasopharyngeal, hematologic, ovarian, endometrial and prostate cancers. A major focus of the work is integrative and multidisciplinary, conducted with colleagues in biostatistics, molecular pathology, cancer biology, genetics and immunology.
A notable strength of the program at Harvard T.H. Chan School of Public Health is its integration into the Dana Farber/Harvard Cancer Center, which enhances opportunities for collaborations with colleagues at other Harvard Medical Area institutions (e.g., Brigham and Women’s Hospital, Massachusetts General Hospital and Dana Farber Cancer Institute).This integration allows researchers to leverage unique data resources, most notably several large prospective cohort and case-control studies. These resources provide superb research opportunities for students and fellows.
Cumulatively, these resources and opportunities result in an exceptionally rich and vibrant academic environment for our students. Past graduates of our program serve as leaders in academia, government, and industry throughout the world.
Meet Us Interview Series
Welcome to our interview series with faculty, postdocs, and students with the Cancer Epidemiology and Cancer Prevention Program!
Check out our YouTube page for new media content.
Data Resources
There are a broad array of data resources, including both cohort and case-control studies, that are based at Harvard Chan School and across the Dana Farber/Harvard Cancer Center. These resources provide unique opportunities to delve deeply into the etiology of cancer risk and progression, to integrate data on the host, genome, and tumor in order to investigate mechanisms, and to translate research into cancer control measures. Below are a summary of just some of the resources available as part of the program in cancer epidemiology and cancer prevention
- Nurses’ Health Study (NHS)
- Nurses’ Health Study II (NHSII)
- Nurses’ Health Study 3 (NHS3)
- Health Professionals Follow-Up Study (HPFS)
- Growing Up Today Study (GUTS)
- Physicians’ Health Study (PHS)
- Women’s Health Study (WHS)
- Southern Community Cohort Study (SCCS)
- Nordic Twin Study of Cancer (NorTwinCan)
- Mammographic Density Study
- IRONMAN Registry
- Pooling Project
- Breast and Prostate Cancer Cohort Consortium (BPC3)
- Epidemiology of Endometrial Cancer Consortium (E2C2)
- Ovarian Cancer Cohort Consortium (OC3)
- Genetic Associations and Mechanisms in Oncology (GAME-ON)
- Clinical Effectiveness Program in Norway (contact: Mette Kalager)
- European Polyp Surveillance Study (EPoS) (Contact: Michael Bretthauer)
- Nordic-European Initiative on Colorectal Cancer (NordICC) (Contact: Michael Bretthauer)
- Norwegian Colorectal Cancer Prevention Trial (NORCCAP) (Contact: Mette Kalager)
Collaborations
- Ireland: ToPCaP
- Brazil: IRONMAN
- Australia: IRONMAN, ToPCaP
- United Kingdom: ToPCaP
- Sweden: NorTwinCan, EPoS, SPCG-4, SPCG-17, SAR
- Norway: NorTwinCan, NORCCAP–I, EPoS, NordICC, Scan-IBD, SAR
- Denmark: NorTwinCan
- Finland: NorTwinCan
- Scotland: EPoS
- Germany: EPoS
- Poland: EPoS
- The Netherlands: EPoS
- Spain: EPoS
- Italy: EPoS, ToPCaP
- Iceland: NordICC, ToPCaP
- Barbados: MadCaP
- Ghana, Nigeria, Senegal, South Africa: MaDCaP
- Greece: EPIC-Greece
- Canada: IRONMAN
- Mexico: IRONMAN, California Teacher’s Cohort
- Uganda: Mbarara University of Science and Technology, PaCT
- South Africa: PaCT
- Tanzania: PaCT
- Nigeria: PaCT
- China: Nanjing Medical University
- Austria: Medical University of Vienna
- Ovarian Cancer Association Consortium
- Breast Cancer Association Consortium: UK, Denmark, Sweden, Netherlands, USA, Canada, Belgium, Poland, Norway, Finland, Germany, Australia, Spain, Portugal, Nigeria, Mexico, Columbia, Israel, Singapore, Malaysia, Japan, South Korea, Russia, Belarus, Macedonia, Greece, Italy
- Oncoarray
- Markers of Density consortium (MODE): UK, Canada, Sweden, Australia, Spain, Germany GWAS of breast cancer
- International Consortium on Mammographic Density (ICDM): France, UK, South Africa, Egypt, Singapore, Turkey, Israel, Mexico, Norway, The Netherlands, Kenya, Korea, Chile, Iran, Poland, Japan, China, Spain
- University of Hawaii
- Memorial Sloan Kettering – NY
- University of California – SF
- University of Southern California
- Vanderbilt University
- Meharry Medical College
- International Epidemiology Institute
- Mayo Clinic (Rochester)
- Dartmouth Cancer Center
- Duke Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- Fred Hutchinson Cancer Research Center
- Cancer Prevention Institute of California
- Johns Hopkins University
- University of Texas, San Antonio
- Michigan State University